System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Ppublish 22 citations

PubMed: 35850011 DOI: 10.1016/j.ebiom.2022.104174

Are mRNA based transcriptomic signatures ready for diagnosing tuberculosis in the clinic? - A review of evidence and the technological landscape.

EBioMedicine 82:104174

Authors: Yohhei Hamada, Adam Penn-Nicholson, Sriram Krishnan, Daniela Maria Cirillo, Alberto Matteelli, Romain Wyss, Claudia M Denkinger, Molebogeng X Rangaka, Morten Ruhwald, Samuel G Schumacher

Affiliations

  • Insitute for Global Health, University College London, London, United Kingdom.
  • FIND, Geneva Switzerland.
  • IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Collaborating Centre for TB/HIV Co-infection and TB Elimination, Dept of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy.
  • FIND, Geneva Switzerland; Division of Tropical Medicine, Centre of Infectious Disease, Heidelberg University Hospital, Heidelberg, Germany; German Center of Infection Research, Partner Site Heidelberg University Hospital, Heidelberg, Germany.
  • Insitute for Global Health, University College London, London, United Kingdom; School of Public Health, and Clinical Infectious Disease Research Institute-AFRICA, University of Cape Town, South Africa.
  • FIND, Geneva Switzerland.

Abstract

Advances in discovery and validation of diagnostic, prognostic and treatment-monitoring transcriptomic signatures of tuberculosis (TB) disease could accelerate the goal to end TB. We conducted a review to evaluate whether mRNA transcriptomics technologies are sufficiently mature to develop accurate next-generation TB diagnostic tests. Early studies tended to be limited in sample size, diversity of population groups, sample collection and processing methods, while recent prospective studies have addressed these limitations. Some of the existing signatures could be used for triage; however, high cost and complexity could limit their use. For a confirmatory test, setting an optimal cut-off to maintain specificity across populations and settings is a challenge. mRNA signatures have shown the potential to quantitatively monitor response to treatment. No prognostic signatures can accurately predict progression to active TB over 2 years while short term prediction is possible. The management strategy should be defined for individuals with positive prognostic tests. FUNDING: Development of this manuscript was supported by funding received from the Stop TB Partnership and USAID for the New Diagnostics Working Group. The funders had no role in paper design, article selection and review, interpretation, or writing of the paper.

MeSH

Tuberculosis, Biomedical Research, Rna, Messenger

Cited by